The outlook of companies tied to Sildenafil's past presents a complex investment picture . While the initial boom generated substantial gains, generic alternatives have significantly eroded sales . Investing in related pharmaceutical businesses now requires a discerning assessment of proprietary rights , evolving healthcare trends , and the prospec